A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

被引：0
|
作者：
Meng, Xiangrui [1 ]
Shan, Zhengzheng [1 ]
Guan, Lulu [1 ]
Dao, Xin [1 ]
Fan, Qingxia [1 ]
Wang, Feng [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-5651-9270-10662; 298-145-222-184-1022-9124; 261-566-9718-9794; 130-540-543-4790; 261-492-2769; 3282-3306-2666-6279; 3282-3306-4614-3827; 3; 2; 2461; 3216; 1704; 239; 6; 1; 38092-34311; 38092-21759; 38116-38094-8; 38092-20072;
D O I：
10.1200/JCO.2024.42.3_suppl.335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：335 / 335
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety analysis of modified biweekly SOX regimen in the first-line treatment of advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma
    Zhang, S.
    Wang, H.
    Meng, Y.
    Nie, X.
    Huang, C.
    Gao, F.
    Sun, L.
    Liu, Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S911 - S911
  • [42] First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
    Hegewisch-Becker, Susanna
    Mendez, Guillermo
    Chao, Joseph
    Nemecek, Radim
    Feeney, Kynan
    Van Cutsem, Eric
    Al-Batran, Salah-Eddin
    Mansoor, Wasat
    Maisey, Nicholas
    Pazo Cid, Roberto
    Burge, Matthew
    Perez-Callejo, David
    Hipkin, R. William
    Mukherjee, Sourav
    Lei, Ming
    Tang, Hao
    Suryawanshi, Satyendra
    Kelly, Ronan J.
    Tebbutt, Niall C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2080 - 2093
  • [43] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Campos Bragagnoli, A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Poulart, V.
    Cullen, D.
    Lei, M.
    Kondo, K.
    Li, M.
    Ajani, J. A.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
  • [44] TREATMENT PATTERNS AND PERFORMANCE STATUS IN UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) PATIENTS RECEIVING FIRST LINE (1L) TREATMENT
    Hall, J.
    Khela, K.
    Middleton-Dalby, C.
    Bertwistle, D.
    Xiao, H.
    VALUE IN HEALTH, 2020, 23 : S485 - S485
  • [45] A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Lui, Arthur
    Mulder, Karen
    Brezden-Masley, Christine
    Vickers, Michael
    Monzon, Jose
    Kennecke, Hagen
    Goel, Rakesh
    Vos, Larissa
    Ghosh, Sunita
    Marginean, Horia
    Fields, Anthony
    Maroun, Jean
    Spratlin, Jennifer
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 674 - 682
  • [46] A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Arthur Lui
    Karen Mulder
    Christine Brezden-Masley
    Michael Vickers
    Jose Monzon
    Hagen Kennecke
    Rakesh Goel
    Larissa Vos
    Sunita Ghosh
    Horia Marginean
    Anthony Fields
    Jean Maroun
    Jennifer Spratlin
    Investigational New Drugs, 2018, 36 : 674 - 682
  • [47] Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
    Hirose, Toshiharu
    Yamamoto, Shun
    Kato, Ken
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [48] Epirubicin, oxaliplatin, and docetaxel (EOD) combination in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A phase II study
    Di Lauro, L.
    Giacinti, L.
    Arena, M. G.
    Fattoruso, S. I.
    Foggi, P.
    Lopez, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Camrelizumab combined with SOX in the first-line treatment of unresectable advanced or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, prospective, and open-label clinical study.
    Liu, Wenlou
    Qin, Xiaobing
    Zhao, Yang
    Ge, Yan
    Tang, Juanjuan
    Wang, Hongmei
    Han, Zhengxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16090 - E16090
  • [50] Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
    Zheng, Bowen
    Lou, Fanzhuoran
    He, Yuting
    Fu, Miao
    Huang, Xintian
    Tan, Weijuan
    Chen, Quan
    Xie, Xiaowen
    Hu, Tianhui
    Xiao, Li
    CANCERS, 2025, 17 (04)
12345